Can a radioactive tracer reveal whether immunotherapy is working?

NCT ID NCT07724535

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial is investigating whether a new radioactive tracer called 18F-grazy-02, used with PET/CT scans, can safely and effectively monitor how well immunotherapy is working in people with lymphoma or solid tumors. The tracer targets granzyme B, a protein released by immune cells when they attack cancer. By measuring tracer uptake in tumors, doctors hope to see early signs of treatment response. The study includes 30 participants and will also track any side effects from the tracer itself.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a radioactive tracer called 18F-grazy-02, used for PET/CT imaging
What this could lead to
If successful, this imaging method could help doctors see early whether immunotherapy is working, potentially guiding treatment decisions without invasive biopsies.
What could go wrong
This is an early-phase trial with only 30 participants, so the tracer's accuracy and safety are still being tested. It may not reliably predict treatment response in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking University Cancer Hospital & Institute

    Beijing, Beijing Municipality, 100142, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.